News Focus
News Focus
Post# of 257253
Next 10
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

Re: Biowatch post# 1483

Sunday, 03/14/2004 9:14:46 PM

Sunday, March 14, 2004 9:14:46 PM

Post# of 257253
Re: Pro-Pharmaceuticals:

[I wonder how much DD the new director did before signing on. The timing sure isn’t fortuitous.]

http://biz.yahoo.com/bw/040312/125418_1.html

>>
Pro-Pharmaceuticals Appoints Jerald K. Rome to Board of Directors

Friday March 12, 2:21 pm ET

NEWTON, Mass.--(BUSINESS WIRE)--March 12, 2004--Pro-Pharmaceuticals, Inc. (Amex: PRW - News), a developer of novel cancer therapeutics to target cancer cells through carbohydrate chemistry, today announced the appointment of Jerald K. Rome to its Board of Directors. Mr. Rome, former Chairman, President and CEO of Moore Medical Corporation, an Amex-listed distributor of national brand pharmaceuticals; a Founder and President of Amberline Pharmaceutical Care Company, a marketer of private label and non-prescription pharmaceuticals, and Vice President and a Director of the National Association of Pharmaceutical Manufacturers.

"We are pleased that Jerry has accepted our invitation to join the Board," said David Platt, Chairman, President & CEO, Pro-Pharmaceuticals, Inc. "His experience and expertise will be invaluable as we advance our cancer therapeutic compounds through clinical trials."

"Pro-Pharmaceuticals has made great strides advancing its drug development program, in particular with the initiation of a Phase II clinical study of its lead carbohydrate compound DAVANAT® with 5-Fluorourcil (5-FU) in refractory colorectal cancer patients," said Mr. Rome. "I look forward to working with the Company through its next phase of growth; bringing cancer therapeutics to market."
<<


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now